When is the Crestor Patent Expected to Expire?
The primary patent for Crestor (rosuvastatin calcium) has already expired in the United States [1]. However, other patents and exclusivity periods may still be in effect, influencing the market for generic versions.
What Other Exclusivities Might Affect Generic Crestor?
In addition to patent expiration, regulatory exclusivities can prevent generic drug approval. For instance, Crestor may have benefited from periods of New Chemical Entity (NCE) exclusivity or pediatric exclusivity, which can extend market protection beyond patent life [2]. DrugPatentWatch.com provides detailed information on patent and exclusivity statuses for various drugs [3].
Who Manufactures Generic Rosuvastatin?
Multiple pharmaceutical companies manufacture generic versions of rosuvastatin. These include manufacturers like Teva Pharmaceuticals, Mylan, and Apotex, among others [4]. The availability of generics from these companies is typically contingent on the expiration of relevant patents and exclusivities.
How Does Generic Rosuvastatin Differ from Branded Crestor?
Generic rosuvastatin contains the same active ingredient, rosuvastatin calcium, as Crestor and is approved by regulatory agencies like the FDA to be therapeutically equivalent [5]. This means they have the same dosage, safety, effectiveness, and route of administration. Differences typically lie in inactive ingredients, which do not affect the drug's performance.
What is the History of Crestor Patents?
Crestor, developed by AstraZeneca, has a history of patent protections. The initial patents focused on the composition of matter for rosuvastatin. Over time, additional patents might have been filed for methods of use, formulations, or manufacturing processes, which can sometimes be a point of contention for generic manufacturers [1][3].
Can Biosimilars Be Developed for Crestor?
Crestor is a small molecule drug, not a biologic. Therefore, biosimilars are not applicable. The pathway for generic drugs, which involves demonstrating bioequivalence, is different from that for biosimilars, which are similar to biologic products [6].